DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Cantor Fitzgerald - 13 Louise Chen - 9 Eli Lilly - 7 Cantor Fitzgerald's Louise Chen Louise Chen - 3 Lilly - 2 Morgan Stanley - 2 David Risinger - 2 Eli Lilly's - 2
Top related locs:
U.S Novo Brussels Belgium United States Bengaluru New York Biopharma
Top related orgs:
Novo Nordisk - 5 Pfizer - 4 Leerink - 3 CNBC - 3 Food - 2 FDA - 2 Novo - 2 pharma - 2

Search resuls for: "Louise Chen"


15 mentions found


☆ Eli Lilly shares could be set for a big move if the Zepbound maker adds to its winning streak
  + stars: | 2024-10-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +6 min
Revenue from obesity treatment Zepbound is forecast to climb to $1.73 billion from $1.24 billion quarter over quarter. For the year, analysts expect Mounjaro sales to reach $4.58 billion, while Zepbound revenue is seen rising to $5.88 billion. The consensus view for combined sales of both drugs now stands at $30.19 billion, according to FactSet. Other key announcements A clinical trial is in progress that pits Zepbound against Novo Nordisk's Wegovy in obesity treatment. Beyond obesity, Lilly has begun treating patients with Kisunla, its Alzheimer's disease treatment.
Persons: Eli Lilly, Lilly, Seamus Fernandez, Morgan Stanley, Terence Flynn, David Risinger, Morgan Stanley's Flynn, Mounjaro, Cantor, Louise Chen, —, Fred Imbert Organizations: Investment, Food, Leerink, Novo Nordisk's, FDA, Kisunla Locations: U.S
☆ Turning point in drug prices is around the corner, says Cantor Fitzgerald's Louise Chen
  + stars: | 2024-09-25 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTurning point in drug prices is around the corner, says Cantor Fitzgerald's Louise ChenLouise Chen, Cantor Fitzgerald senior analyst, joins ‘Squawk Box’ to discuss Novo Nordisk's CEO on Capitol Hill, when drug prices could start to come down, and more.
Persons: Cantor Fitzgerald's Louise Chen Louise Chen, Cantor Fitzgerald Organizations: Novo, Capitol
☆ Eli Lilly and Novo Nordisk are ahead in manufacturing but need time to meet demand, says Louise Chen
  + stars: | 2024-06-27 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly and Novo Nordisk are ahead in manufacturing but need time to meet demand, says Louise ChenLouise Chen, Cantor Fitzgerald analyst, joins CNBC's 'Squawk Box' to discuss Eli Lilly's surge over the past year, manufacturing, and more.
Persons: Eli Lilly, Louise Chen Louise Chen, Cantor Fitzgerald, Eli Lilly's Organizations: Novo Nordisk
☆ A corner of the cancer therapy market is heating up—Here are the names investors need to know
  + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com   time to read: +8 min
A $25 billion market Meanwhile, RBC Capital Markets sees a $25 billion market opportunity for the space. A name Jones likes is Perspective Therapeutics , which he rates outperform. CATX 1Y mountain Perspective Therapeutics year to date Cantor Fitzgerald is also bullish on the name. So it's really an ideal profile," said Piper Sandler analyst Edward Tenthoff, who doesn't cover Perspective Therapeutics. Then there is Lantheus Holdings , which calls itself a radiopharmaceutical-focused company and has a $5.6 billion market cap.
Persons: There's, Eli Lilly, Myers, Jefferies, Andrew Tsai, radiopharma, Oppenheimer, Jeff Jones, FactSet, William Blair, Read, — it's, Andy Hsieh, Gregory Renza, Jones, Cantor Fitzgerald, Louise Chen, it's, Piper Sandler, Edward Tenthoff, Dan Lyons, Janus Henderson, Lantheus, Roanna Ruiz Organizations: Novartis, pharma, Mariana Oncology, Myers Squibb, AstraZeneca, Fusion Pharmaceuticals, RBC Capital Markets, TRT, Therapeutics, Alpha, Janus, Janus Henderson Investors, Lantheus Holdings, Lantheus, Leerink, ~$ Locations: Biopharma, Bristol, Mariana, radiopharma, New Jersey
☆ Eli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise Chen
  + stars: | 2024-04-30 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise ChenLouise Chen, Cantor Fitzgerald managing director, joins 'Squawk Box' to discuss Eli Lilly's quarterly earnings results, weight loss drug demand, growth outlook, and more.
Persons: Eli Lilly, Cantor Fitzgerald's Louise Chen Louise Chen, Cantor Fitzgerald, Eli
☆ Pfizer's expectations have been rightsized, has potential for $5 EPS: Cantor Fitzgerald's Chen
  + stars: | 2024-02-22 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer's expectations have been rightsized, has potential for $5 EPS: Cantor Fitzgerald's ChenLouise Chen, Cantor Fitzgerald, and Michael Yee, Jefferies, joins 'Power Lunch' to discuss Chen's bull case for Pfizer, Yee's bull case for Moderna, and more.
Persons: Fitzgerald's Chen Louise Chen, Cantor Fitzgerald, Michael Yee, Jefferies Organizations: Pfizer, Moderna
☆ Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
  + stars: | 2024-02-10 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +8 min
Victoria Klesty | ReutersThe insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly , have said supply woes likely won't go away anytime soon, as the popularity of those medicines continues to soar. Some Wall Street analysts project that the weight loss drug market could be worth $100 billion by the end of the decade. But both Novo Nordisk and Eli Lilly gave updates on positive supply developments to investors over the last week. Other forms of weight loss drugs could helpAlternative forms of weight loss drugs could also help alleviate supply constraints in the future.
Persons: Victoria Klesty, Eli Lilly, Cantor Fitzgerald, Louise Chen, Nordisk's Wegovy, Eli Lilly's Zepbound, Goldman Sachs, Jeff Friedman, Novo, Mike Segar, Eli, Catalent, Yves Herman Yves Herman, TD Cowen, Michael Nedelcovych, Anat Ashkenazi, Cantor Fitzgerald's Chen, Morgan Stanley, Eli Lilly's, George Frey Organizations: Novo Nordisk, CNBC, Nordisk's, University of Florida, Pfizer, AstraZeneca, Roche, Food, Nordisk, Company, FDA, Novo Holdings, Wegovy, REUTERS, Reuters, U.S Locations: Oslo, Norway, Novo, U.S, Branchburg , New Jersey, Brussels, Belgium, Catalent, Concord , North Carolina, North, Germany, Indiana, Denmark, France
☆ There's still a long runway for obesity drugs, says Cantor Fitzgerald's Louise Chen
  + stars: | 2023-12-01 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThere's still a long runway for obesity drugs, says Cantor Fitzgerald's Louise ChenLouise Chen, Cantor Fitzgerald analyst, joins 'Squawk on the Street' to discuss what's already priced into the big GLP-1 manufacturing stocks, Chen's thoughts on these companies over the long-term, and much more.
Persons: Cantor Fitzgerald's Louise Chen Louise Chen, Cantor Fitzgerald
☆ Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success
  + stars: | 2023-11-13 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
As its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market. Those companies helped spark the weight loss drug industry gold rush over the last year with their weekly obesity and diabetes injections, such as Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Mounjaro. They want to see the drug cause a similar level of weight loss as a once-daily pill from Eli Lilly. "If Pfizer's data is positive, then I think people might be able to look beyond all this Covid overhang," Cantor Fitzgerald analyst Louise Chen told CNBC. A weight loss pill could be a boon for all three companies.
Persons: Eli Lilly, Eli Lilly's Mounjaro, Albert Bourla, –, Cantor Fitzgerald, Louise Chen Organizations: Pfizer, Novo Nordisk, Nordisk's Wegovy, CNBC
☆ Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
  + stars: | 2023-10-29 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +11 min
Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don't expect this duopoly to end soon, analysts say. All this goes on amid robust demand for Novo's semaglutide, which is sold as Ozempic for type 2 diabetes and as Wegovy for weight loss, and Lilly's tirzepatide, which hopes to receive regulatory approval for weight loss this year. Orforglipron is an oral drug Eli Lilly is developing. It has several other compounds in the pipeline, but Suvannavejh expects the weight loss drug to receive increased attention. "This range would also be competitive with LLY's orforglipron [an oral GLP-1 drug] weight loss at day 28," Smith said.
Persons: Eli Lilly, Piper Sandler, Yasmeen Rahimi, Cantor Fitzgerald, Louise Chen, Lilly, Lilly's, Chen, Price, Kyle Rasbach, We've, Rasbach, Altimmune Altimmune, NASH, Piper's, Rahimi, Cantor's Chen, it's, Eli Lilly's Mounjaro, Goldman Sachs, Chris Shibutani, David Risinger, Risinger, Jonathan Wolleben, Wolleben, Orforglipron, Graig Suvannavejh, Suvannavejh, Thomas Smith, LLY's, Smith, Yale Jen, Jen Organizations: Novo Nordisk, Pfizer, Novo, pharma, Pfizer Pfizer, danuglipron, Therapeutics, Leerink, Mizuho Securities, Viking Therapeutics Viking Therapeutics, Laidlaw & Co Locations: Novo, GLP, Eventide
☆ J&J lifts profit outlook on strong demand for top-seller Stelara
  + stars: | 2023-10-17 | by ( Bhanvi Satija Patrick Wingrove | Bhanvi Satija | Patrick Wingrove | ) www.reuters.com   time to read: +3 min
The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. Investors are focused on how J&J, now a standalone pharmaceutical and medical devices company, will reach its goal of $57 billion in drug sales by 2025. Johnson & Johnson recorded a $21-billion gain in the third quarter from the spin-off of its consumer health unit. Stelara, J&J's top-selling anti-inflammatory drug, brought in sales of $2.86 billion in the quarter, above LSEG estimates of $2.61 billion. Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, compared with its previous outlook of $10.00 to $10.10 per share.
Persons: Johnson, Yves Herman, MedTech, Cantor Fitzgerald, Louise Chen, Stelara, Joseph Wolk, Wolk, J, Bhanvi Satija, Sriparna Roy, Patrick Wingrove, Shounak Dasgupta Organizations: Johnson, REUTERS, Innovative Medicine, Reuters, Thomson, & $, & $ Locations: Brussels, Diegem, Belgium, Stelara, U.S, United States, Bengaluru, New York
☆ Ozempic could be the next target of Medicare drug price negotiations – here's why
  + stars: | 2023-08-31 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Ozempic, the blockbuster diabetes treatment from Novo Nordisk , could be next in line in the price negotiations between manufacturers and Medicare. Ozempic will likely be eligible for negotiations by the time the next round of drugs is selected in 2025, for price changes that will go into effect in 2027. Novo Nordisk's Rybelsus, a diabetes drug taken orally, could also be on the list because it contains the same active ingredient as Ozempic. A spokesperson for Novo Nordisk didn't directly comment on the potential for Ozempic to be included in the next round of talks. Medicare and private insurers typically secure discounts and rebates on the drugs they cover, but it's unclear how large they are.
Persons: Biden, Ozempic, Cantor Fitzgerald, Louise Chen, Elon Musk Organizations: Novo Nordisk, Pharmacy, Ozempic, CNBC, Novo Nordisk's Rybelsus, Medicare, Services, Elon Locations: Provo , Utah, U.S, Novo
☆ Cantor's Louise Chen breaks down new Medicare drug pricing negotiations
  + stars: | 2023-08-29 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCantor's Louise Chen breaks down new Medicare drug pricing negotiationsLouise Chen, Cantor Fitzgerald, joins 'Power Lunch' to discuss Medicare drug priced ahead of Biden's news conference on the negotiations.
Persons: Louise Chen, Cantor Fitzgerald
☆ Merck beats quarterly sales estimate on top drugs' strength
  + stars: | 2023-08-01 | by ( Michael Erman | ) www.reuters.com   time to read: +3 min
Companies Merck & Co Inc FollowAug 1 (Reuters) - Merck & Co (MRK.N) posted better-than-expected second-quarter sales on Tuesday on strong demand for its two top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil. Shares of Merck rose about 2% at $108.45 in premarket trading after the company also raised its full-year revenue forecast. Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion. Sales of Gardasil, which prevents cancers caused by HPV, surged 47% to $2.5 billion, also well above Wall Street estimates of $2.1 billion. Merck said it now expects full-year sales of $58.6 to $59.6 billion, up from its prior view of $57.7 billion to $58.9 billion.
Persons: Merck, Rob Davis, Davis, Keytruda, Cantor Fitzgerald, Louise Chen, Prometheus, drugmaker, Michael Erman, Leroy Leo, Bill Berkrot Organizations: Merck, Co, Merck & Co, Merck's, Prometheus Biosciences, Analysts, Prometheus, Thomson Locations: United States, China, U.S, New York, Bengaluru
☆ Johnson & Johnson's consumer health unit Kenvue started trading. What it means for J&J shareholders like us
  + stars: | 2023-05-05 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +9 min
For now, it's not exactly clear how J & J will go about the second step of this divestiture. In this scenario, we would have the option to relinquish some, all or none of our J & J shares. In fact, our optimism around the breakup was a big reason we bought into J & J nearly a year ago . J & J continues to argue against claims that its baby powder and other talc products caused cancer lack merit. "Look at it as a whole company today, knowing that [roughly] 10% doesn't belong to J & J," explained Cantor Fitzgerald analyst Louise Chen, who has a buy rating and maintains a $215 price target on J & J.
0 next >>
Total: 15